Jazz Pharmaceuticals (JAZZ) Given News Sentiment Rating of 0.22
News coverage about Jazz Pharmaceuticals (NASDAQ:JAZZ) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Jazz Pharmaceuticals earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 44.5134093221021 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment’s analysis:
- ETFs with exposure to Jazz Pharmaceuticals Plc : December 26, 2017 (finance.yahoo.com)
- Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 (finance.yahoo.com)
- Jazz Submits NDA to FDA for JZP-110 to Cure Sleep Disorder – Nasdaq (nasdaq.com)
- Jazz Pharmaceuticals (JAZZ) Submits NDA for Solriamfetol for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea (streetinsider.com)
- Jazz Pharmaceuticals Submits New Drug Application for Solriamfet – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
Several analysts recently commented on JAZZ shares. Stifel Nicolaus reiterated a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 30th. Royal Bank of Canada reiterated a “buy” rating and set a $210.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, September 15th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 18th. BMO Capital Markets reiterated a “buy” rating and set a $196.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 20th. Finally, UBS Group reiterated a “buy” rating and set a $172.00 price target (down from $175.00) on shares of Jazz Pharmaceuticals in a research report on Monday, September 25th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and an average price target of $181.28.
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) traded down $0.24 during trading hours on Thursday, reaching $135.03. The company’s stock had a trading volume of 290,000 shares, compared to its average volume of 504,537. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. The stock has a market cap of $7,960.00, a PE ratio of 22.25, a P/E/G ratio of 0.86 and a beta of 0.97. Jazz Pharmaceuticals has a 12 month low of $106.65 and a 12 month high of $163.75.
In other news, SVP Iain Mcgill sold 8,000 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.42, for a total value of $1,067,360.00. Following the transaction, the senior vice president now owns 28,383 shares of the company’s stock, valued at approximately $3,786,859.86. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total value of $150,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,552 shares of company stock valued at $2,549,643. 4.30% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theolympiareport.com/2017/12/28/jazz-pharmaceuticals-jazz-given-news-sentiment-rating-of-0-22.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.